P176 Ixekizumab significantly improves nail disease and adjacent joint tenderness and swelling in psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. P176 Ixekizumab significantly improves nail disease and adjacent joint tenderness and swelling in psoriatic arthritis. Rheumatology 2024, 63: keae163.215. DOI: 10.1093/rheumatology/keae163.215.Peer-Reviewed Original ResearchPost-baseline assessmentTreatment effectsEli Lilly and CompanyPost hoc analysisSevere functional impairmentStudy of adultsNail PsOFunctional impairmentAdjacent joint diseaseSPIRIT-H2HGroup levelHoc analysisPsoriatic arthritisJoint tendernessNail diseaseIndividual digitsPatients treated with ixekizumabNon-respondersEli LillyUCB PharmaJoint involvementJoint swellingCorEvitas Psoriasis RegistryCount scoreTreated with adalimumab503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice
Wang Z, Martins B, Ardeleanu M, Yang M, Bégo-Le-Bagousse G, Sierka D, Strober B. 503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice. British Journal Of Dermatology 2024, 190: ii9-ii9. DOI: 10.1093/bjd/ljad498.011.Peer-Reviewed Original ResearchHealth statusIndividual patient levelTreatment satisfactionAtopic Dermatitis Control ToolPatient levelQuality of life of childrenObservational study of adultsAtopic dermatitisLongitudinal cohort studyPatient-reported outcomesPatient support programStudy of adultsQuality of lifeDupilumab treatmentMonth 1Lives of childrenBaseline surveyChronic inflammatory skin diseasePatients maintained responseSupport programsModerate-to-severe ADCohort studyLong-term treatmentInflammatory skin diseaseOutcome trajectories